

# Dialysis & Nephrology DIGEST

A monthly report by Benesch on the  
Dialysis & Nephrology Industry

## In This Issue

---

### PAGE 2

#### **Calendar of Events**

---

### PAGE 4

#### **Nephrology and Dialysis**

Peritoneal dialysis, hemodialysis offer similar survival outcomes for ESRD patients

Women with chronic kidney disease face barriers to contraceptive, reproductive care

---

### PAGE 5

DeLorean AI targets early detection to transform chronic kidney disease care

CMS finalizes CY 2026 ESRD payment rule with rate increase and program changes

---

### PAGE 6

Global CRRT market set for rapid growth, driven by technology, patient-centric care

FDA approves Otsuka kidney disease therapy

---

### PAGE 7

Femoral dialysis catheter survival unaffected by initial dialysis modality, study finds

Climate change intensifies kidney disease risks, strains dialysis systems

---

### PAGE 8

Proteomic analysis reveals mortality risk factors in hemodialysis patients

CMS to end experiment to fix kidney failure two years early

---

### PAGE 9

Dialysis equipment market set to nearly double as home-based, AI-enabled technologies gain ground

U.S. senator urges release of FTC findings on dialysis industry dominance

Study links chronic kidney disease to faster cognitive decline, with stronger effects seen in men

---

### PAGE 10

#### **VAC, ASC and Office-Based Labs**

Sigyn Therapeutics introduces CardioDialysis™ to target cardiovascular disease in dialysis patients

Bayer launches Phase IIa trial of antibody for Alport syndrome

## Dialysis & Nephrology DIGEST



Please contact us if you would like to post

information regarding our upcoming events or if you'd like to guest author an article for this newsletter.

[sdowning@beneschlaw.com](mailto:sdowning@beneschlaw.com)

[jgreis@beneschlaw.com](mailto:jgreis@beneschlaw.com)

[jcilek@beneschlaw.com](mailto:jcilek@beneschlaw.com)

### Calendar of Events

MARCH 1–4, 2026

**American Venous Forum 2026**

Denver, CO

For more information, please click [here](#).

MARCH 19–21, 2026

**2026 OEIS Scientific Meeting**

Las Vegas, NV

For more information, please click [here](#).

APRIL 16–19, 2026

**RPA 2026 Annual Meeting**

Atlanta, GA

For more information, please click [here](#).

OCTOBER 21–25, 2026

**ASN: Kidney Week 2026**

Denver, CO

For more information, please click [here](#).

SAVE THE DATE

**Benesch Healthcare+ Sixth Annual Nephrology and Dialysis Conference**

**Thursday, June 25, 2026**

**Sheraton Grand Chicago Riverwalk**  
**301 E North Water Street**  
**Chicago, IL**




**Benesch Healthcare+**

The content of the Benesch, Friedlander, Coplan & Aronoff LLP *Dialysis & Nephrology Digest* is for general information purposes only. It does not constitute legal advice or create an attorney-client relationship. Any use of this newsletter is for personal use only. All other uses are prohibited. ©2025 Benesch, Friedlander, Coplan & Aronoff LLP. All rights reserved.

---

## Dialysis & Nephrology DIGEST

# Effective Tools and Resources for Your Nephrology Practice



[www.renalmd.org](http://www.renalmd.org)

The content of the Benesch, Friedlander, Coplan & Aronoff LLP *Dialysis & Nephrology Digest* is for general information purposes only. It does not constitute legal advice or create an attorney-client relationship. Any use of this newsletter is for personal use only. All other uses are prohibited. ©2025 Benesch, Friedlander, Coplan & Aronoff LLP. All rights reserved.

## Dialysis & Nephrology DIGEST

### Nephrology and Dialysis

OCTOBER 31, 2025

#### **Peritoneal dialysis, hemodialysis offer similar survival outcomes for ESRD patients**

A systematic review and meta-analysis of 27 observational studies involving over 1,000,000 incident dialysis patients found that peritoneal dialysis (PD) and in-center hemodialysis provide equivalent overall survival for individuals with end-stage renal disease (ESRD). The analysis included contemporary cohorts of adults initiating dialysis after 2000 and assessed mortality using propensity-matched hazard ratios. While overall survival was similar, subgroup analyses revealed age- and region-specific differences—PD was associated with lower mortality in patients under 65 and showed modestly better outcomes in Europe and North America, whereas higher hazard ratios were observed in Asia and Oceania. No significant differences were seen based on sex, diabetes status, dialysis vintage or cohort inclusion period. These findings support individualized dialysis modality selection based on patient preferences, clinical characteristics and access considerations.

Source: HCP Live

NOVEMBER 5, 2025

#### **Women with chronic kidney disease face barriers to contraceptive, reproductive care**

A recent study highlights significant challenges faced by women with chronic kidney disease (CKD) in accessing contraceptive options and comprehensive reproductive health services. Key barriers include limited availability of suitable contraceptives, inadequate patient education and insufficient integration of reproductive care within nephrology practices. These gaps are particularly concerning given the increased risks CKD poses during pregnancy, making family planning and tailored counseling essential for patient safety. The

*(continued on next page)*


## Building tomorrow's kidney care leaders, today.



The RPA Dale Singer Leadership and Education Foundation—named for the late RPA Executive Director Dale Singer—invests in nephrology professionals, especially those early in their careers, through leadership development, mentorship, and education. We're building a resilient, innovative workforce equipped to tackle policy challenges and ready to shape the future of kidney care.

**GIVE NOW**

[www.renaldmd.org](http://www.renaldmd.org)



The RPA Singer Foundation is a 501c3 nonprofit organization and your contribution is tax-deductible to the extent allowed by law.



**Scan to donate**  
or click the  
Give Now button

The content of the Benesch, Friedlander, Coplan & Aronoff LLP *Dialysis & Nephrology Digest* is for general information purposes only. It does not constitute legal advice or create an attorney-client relationship. Any use of this newsletter is for personal use only. All other uses are prohibited. ©2025 Benesch, Friedlander, Coplan & Aronoff LLP. All rights reserved.

## Dialysis & Nephrology DIGEST

### Nephrology and Dialysis (cont'd)

study underscores the need for nephrology providers to proactively address reproductive health, offering guidance on safe contraceptive use, pregnancy management and individualized care plans. Strengthening these services can improve outcomes, enhance patient autonomy and ensure that women with CKD receive holistic, patient-centered care that meets their unique medical and reproductive needs.

Source: GOAI

---

NOVEMBER 6, 2025

#### **DeLorean AI targets early detection to transform chronic kidney disease care**

DeLorean AI is seeking to disrupt chronic kidney disease care by using precision predictive analytics to identify renal decline years before patients require dialysis or transplant. By analyzing longitudinal electronic health record data, DeLorean AI's models aim to flag high-risk patients up to 24 months earlier than standard clinical monitoring and recommend clear, actionable interventions. The company emphasizes transparency, providing clinicians and patients with understandable predictions supported by historical data. Early detection could be especially impactful for populations disproportionately affected by kidney failure, including Black and Latino patients, who are more likely to face delayed diagnosis and limited access to specialty care.

Source: Forbes

---

NOVEMBER 20, 2025

#### **CMS finalizes CY 2026 ESRD payment rule with rate increase and program changes**

On November 20, 2025, the Centers for Medicare & Medicaid Services (CMS) issued a final rule updating payment rates and policies under the End-Stage Renal Disease (ESRD) Prospective Payment System for calendar year 2026. Effective January 1, 2026, the ESRD PPS base rate will increase to \$281.71, reflecting a 2.2% projected rise in total payments to dialysis facilities nationwide. The rule also establishes a new non-labor cost payment adjustment for ESRD facilities in Alaska, Hawaii and the U.S. Pacific Territories, aligning the acute kidney injury dialysis rate with the updated base rate. In addition, CMS shortens the ICH CAHPS patient survey, removes three health equity reporting measures from the ESRD Quality Incentive Program, and finalizes the early termination of the ESRD Treatment Choices Model.

Source: Centers for Medicare & Medicaid Services

---

## Nephrology and Dialysis (cont'd)

NOVEMBER 21, 2025

### Global CRRT market set for rapid growth, driven by technology, patient-centric care

The global Continuous Renal Replacement Therapy (CRRT) market is entering a period of rapid expansion, fueled by rising acute kidney injury incidence, technological innovation and a shift toward patient-centered critical care. Valued at several billion dollars, the market is projected to reach approximately \$2.6 billion by 2030, growing at a CAGR of 7.5-10.9%. North America currently leads the market, supported by advanced healthcare infrastructure and strong reimbursement frameworks, while Europe benefits from government initiatives and research investments. Asia-Pacific is the fastest-growing region, driven by healthcare modernization and domestic device manufacturing. Key trends include smart, portable CRRT platforms, sorbent-based and nanotechnology enhancements, and remote monitoring capabilities. Increasing ICU admissions, aging populations and government programs promoting early detection of kidney disease are expected to further propel market growth, aligning technological progress with compassionate, patient-focused renal care.

Source: OpenPR

---

NOVEMBER 25, 2025

### FDA approves Otsuka kidney disease therapy

The FDA approved Voyxact, a drug from Otsuka, for the treatment of IgA nephropathy (IgAN), a chronic autoimmune kidney disease that can lead to progressive kidney failure and the need for dialysis. This is the first approval in a new class of medicines for this condition. The approval provides nephrologists and their patients with a new treatment option, potentially impacting the dialysis marketplace by delaying or reducing the need for dialysis in IgAN patients. No legal or reimbursement issues were discussed in the article.

Source: STAT 10

---

## Dialysis & Nephrology DIGEST



The content of the Benesch, Friedlander, Coplan & Aronoff LLP *Dialysis & Nephrology Digest* is for general information purposes only. It does not constitute legal advice or create an attorney-client relationship. Any use of this newsletter is for personal use only. All other uses are prohibited. ©2025 Benesch, Friedlander, Coplan & Aronoff LLP. All rights reserved.

---

## Nephrology and Dialysis (cont'd)

NOVEMBER 25, 2025

### **Femoral dialysis catheter survival unaffected by initial dialysis modality, study finds**

A retrospective study analyzed femoral vein catheter outcomes in 279 patients (318 cases) undergoing hemodialysis or continuous renal replacement therapy (CRRT) between 2019 and 2023. Researchers compared catheter survival according to the initial dialysis modality and clinical factors. Among 303 femoral catheterizations included in the final analysis, overall catheter survival didn't differ significantly between the hemodialysis and CRRT groups. Body mass index (BMI) emerged as a key factor influencing catheter longevity, particularly in CRRT patients, where higher BMI, older age and elevated platelet counts were associated with reduced catheter survival. No specific factors significantly impacted catheter survival in the hemodialysis group. The study concludes that femoral dialysis catheter longevity is independent of the initial dialysis modality, though patient characteristics such as BMI may affect outcomes in CRRT recipients.

**Source:** [Springer Nature Link](#)

---

NOVEMBER 26, 2025

### **Climate change intensifies kidney disease risks, strains dialysis systems**

Climate change is emerging as a major and underrecognized threat to kidney health, particularly for people living with chronic kidney disease and end-stage renal disease. Rising temperatures and more frequent heat waves increase dehydration, heat stress, acute kidney injury and hospitalizations, while climate-driven disruptions such as flooding and power outages can delay life-saving dialysis treatments. Research shows heat exposure may accelerate kidney function decline, especially among vulnerable patients and outdoor laborers, contributing to the growing burden of climate-associated kidney disease. At the same time, dialysis itself carries a substantial environmental footprint through high water, energy and plastic waste use. Experts argue that climate-smart kidney care is urgently needed to protect patients, reduce inequities and align kidney care with planetary health goals.

**Source:** [Forbes](#)

---

## Dialysis & Nephrology DIGEST

## Dialysis & Nephrology DIGEST

### Nephrology and Dialysis (cont'd)

NOVEMBER 28, 2025

#### **Proteomic analysis reveals mortality risk factors in hemodialysis patients**

A recent study published in Nature Communications leverages high-throughput proteomic profiling to uncover previously unrecognized mortality risk factors in patients undergoing hemodialysis. Researchers analyzed plasma samples from the Chronic Renal Insufficiency Cohort and Predictors of Arrhythmic and Cardiovascular Events study, identifying molecular signatures linked to systemic inflammation, endothelial dysfunction and extracellular matrix remodeling. These proteomic markers outperformed traditional clinical risk scores in predicting survival and revealed patient subpopulations with distinct pathophysiological trajectories, highlighting opportunities for precision nephrology interventions. Temporal profiling further enabled early detection of shifts in risk before clinical deterioration. The findings suggest that integrating proteomic data with machine learning, electronic health records and wearable biosensors could transform individualized care—enabling proactive therapeutic strategies to reduce mortality in end-stage renal disease.

**Source: Bioengineer**

---

DECEMBER 1, 2025

#### **CMS to end experiment to fix kidney failure two years early**

The Centers for Medicare and Medicaid Services (CMS) will end its End-Stage Renal Disease Treatment Choices (ETC) model on December 31, as announced in a final rule. The ETC model, the largest experiment of its kind in U.S. healthcare, aimed to incentivize dialysis providers to increase home dialysis and kidney transplants by offering financial rewards. Despite requiring participation from 30% of U.S. dialysis providers, analyses from 2021 and a subsequent study found no significant impact on rates of home dialysis or transplantation compared to control groups. As a result, CMS is discontinuing the program due to a lack of demonstrated effectiveness in changing dialysis delivery patterns.

**Source: STAT 10**

---

## Dialysis & Nephrology DIGEST

### Nephrology and Dialysis (cont'd)

DECEMBER 3, 2025

#### **Dialysis equipment market set to nearly double as home-based, AI-enabled technologies gain ground**

The global dialysis equipment market is expanding rapidly, driven by the rising prevalence of chronic kidney disease and end-stage renal disease (ESRD), alongside advances in technology and supportive reimbursement policies. Valued at \$98.6 billion in 2024, the market is projected to reach \$191.2 billion by 2032, reflecting a compound annual growth rate of 8.65%. Growth is fueled by increasing rates of diabetes, hypertension and population aging, with more than 70% of ESRD patients dependent on dialysis. Innovations such as home hemodialysis systems, wearable artificial kidneys, AI-enabled monitoring and automated peritoneal dialysis are reshaping care delivery. While high costs and workforce shortages pose challenges in some regions, strong adoption in North America and accelerating growth in Asia Pacific are positioning the market for sustained, long-term expansion.

Source: Industry Today

---

DECEMBER 8, 2025

#### **U.S. senator urges release of FTC findings on dialysis industry dominance**

U.S. Senator Richard Blumenthal is pressing federal regulators to disclose the results of an investigation into the dialysis industry, warning that extreme market concentration may be harming patient care. Two companies, Fresenius and DaVita, control nearly three-quarters of U.S. dialysis clinics, a level critics describe as a duopoly with hallmarks of anti-competitive behavior. Blumenthal argues the FTC hasn't used its full antitrust authority despite concerns about quality and access. Academic research and federal data link consolidation to lower transplant referrals and weaker outcomes, while the companies dispute these claims and defend the quality of their care.

Source: CBS News

---

DECEMBER 8, 2025

#### **Study links chronic kidney disease to faster cognitive decline, with stronger effects seen in men**

Chronic kidney disease (CKD) may accelerate cognitive decline through damage to the interconnected kidney-heart-brain axis, with distinct effects in men and women, according to a recent study. Researchers at Marshall University found that men with CKD experienced greater cognitive impairment and more pronounced declines in heart function than women with the same condition. Published in the American Journal of Physiology–Heart and Circulatory Physiology, the study analyzed a rural, community-dwelling population and identified stronger links between cardiac dysfunction and cognitive decline in men. The findings suggest that biological pathways connecting kidney, cardiovascular and brain health differ by sex.

Source: The Hindu

---

## Dialysis & Nephrology DIGEST

### VAC, ASC and Office-Based Labs

NOVEMBER 6, 2025

#### **Sigyn Therapeutics introduces CardioDialysis™ to target cardiovascular disease in dialysis patients**

Sigyn Therapeutics released a shareholder letter outlining CardioDialysis™, a dialysis-compatible medical device designed to treat cardiovascular disease, the leading cause of death globally and the primary cause of mortality among end-stage renal disease patients. CardioDialysis™ uses blood purification to simultaneously reduce inflammatory molecules and cholesterol-transporting lipoproteins associated with major adverse cardiovascular events. The company plans to initially enroll kidney dialysis patients in FDA human studies, citing a 67% cardiovascular mortality rate in this population.

Leveraging more than 7,500 dialysis clinics and existing dialysis machine infrastructure in the U.S., Sigyn aims to integrate CardioDialysis™ into routine dialysis care. If successful, the therapy could transform dialysis clinics into combined renal and cardiovascular treatment centers, improve patient outcomes, and create new revenue opportunities for the dialysis industry.

**Source: Sigyn Therapeutics**

---

DECEMBER 7, 2025

#### **Bayer launches Phase IIa trial of antibody for Alport syndrome**

Bayer initiated a Phase IIa clinical trial evaluating BAY 3401016, an investigational monoclonal antibody designed to block Semaphorin 3A, a protein believed to contribute to kidney damage in Alport syndrome. The randomized, double-blind, placebo-controlled ASSESS study will assess the efficacy and safety of the therapy in adults with the rare genetic condition, which leads to progressive kidney failure and often end-stage renal disease. Alport syndrome currently has no approved disease-specific treatments, and patients typically experience declining kidney function despite standard care. BAY 3401016 aims to reduce proteinuria and slow loss of kidney function. The program, developed through Bayer's collaboration with Evotec, has received both FDA Fast Track and Orphan Drug designations.

**Source: Bayer**

---

## Dialysis & Nephrology DIGEST

For more information regarding our nephrology, dialysis and office-based lab experience, or if you would like to contribute to the newsletter, please contact:

**Jake Cilek** | [jcilek@beneschlaw.com](mailto:jcilek@beneschlaw.com) | 312.624.6363

**Scott Downing** | [sdowning@beneschlaw.com](mailto:sdowning@beneschlaw.com) | 312.624.6326

**Jason Greis** | [jgreis@beneschlaw.com](mailto:jgreis@beneschlaw.com) | 312.624.6412

### Advertise with Us!

---

To advertise in Benesch's Dialysis & Nephrology Digest, please contact:

**Sarah Ross** at [ross@beneschlaw.com](mailto:ross@beneschlaw.com) | 216.363.6178